If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X Vol 5.1 • October 2017 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> ESMO 2017<br /> Madrid, Spain<br /> CONTENTS<br /> EDITORIAL BOARD....................................................................................................................................... 4<br /> CONGRESS REVIEW..................................................................................................................................... 12<br /> • Review of the European Society of Medical Oncology (ESMO) Congress 2017, held in<br /> Madrid, Spain, 8th–12th September 2017<br /> INTERVIEWS WITH EMJ ONCOLOGY EDITORIAL BOARD................................................................. 31<br /> ABSTRACT REVIEWS.................................................................................................................................. 38<br /> ARTICL<a title="EMJ Oncology 5.1 2017 page 1" href="http://viewer.zmags.com/publication/6f2ba9ec?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 5.1 2017 page 2" href="http://viewer.zmags.com/publication/6f2ba9ec?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Oncology 5.1 2017 page 3" href="http://viewer.zmags.com/publication/6f2ba9ec?page=3"> ONCOLOGY • PROGNOSTIC AND PREDICTIVE VALUE OF F</a> <a title="EMJ Oncology 5.1 2017 page 4" href="http://viewer.zmags.com/publication/6f2ba9ec?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Dr Ahmad Awada,</a> <a title="EMJ Oncology 5.1 2017 page 5" href="http://viewer.zmags.com/publication/6f2ba9ec?page=5"> ONCOLOGY AIMS AND SCOPE • The European Me</a> <a title="EMJ Oncology 5.1 2017 page 6" href="http://viewer.zmags.com/publication/6f2ba9ec?page=6"> ONCOLOGY 5.1 OCTOBER 2017 Director Spencer Gore</a> <a title="EMJ Oncology 5.1 2017 page 7" href="http://viewer.zmags.com/publication/6f2ba9ec?page=7"> Welcome A very warm welcome to the 2017 editio</a> <a title="EMJ Oncology 5.1 2017 page 8" href="http://viewer.zmags.com/publication/6f2ba9ec?page=8"> IdyllaTM RAS Liquid Biopsy Testing for Clinical U</a> <a title="EMJ Oncology 5.1 2017 page 9" href="http://viewer.zmags.com/publication/6f2ba9ec?page=9"> Foreword Dr Luís Costa Hospital de Santa </a> <a title="EMJ Oncology 5.1 2017 page 10" href="http://viewer.zmags.com/publication/6f2ba9ec?page=10"> Novartis Pharma AG CH-4002 Basel Switzerland </a> <a title="EMJ Oncology 5.1 2017 page 11" href="http://viewer.zmags.com/publication/6f2ba9ec?page=11"> AML is swarming with challenges Strikingly heter</a> <a title="EMJ Oncology 5.1 2017 page 12" href="http://viewer.zmags.com/publication/6f2ba9ec?page=12"> </a> <a title="EMJ Oncology 5.1 2017 page 13" href="http://viewer.zmags.com/publication/6f2ba9ec?page=13"> ESMO ANNUAL CONGRESS 2017 IFEMA-FERIA DE MADRID,</a> <a title="EMJ Oncology 5.1 2017 page 14" href="http://viewer.zmags.com/publication/6f2ba9ec?page=14"> dedicated to each branch of cancer, with a</a> <a title="EMJ Oncology 5.1 2017 page 15" href="http://viewer.zmags.com/publication/6f2ba9ec?page=15"> Hybrid Minimally Invasive Oesophagectomy for Oeso</a> <a title="EMJ Oncology 5.1 2017 page 16" href="http://viewer.zmags.com/publication/6f2ba9ec?page=16"> While the study authors noted the survival </a> <a title="EMJ Oncology 5.1 2017 page 17" href="http://viewer.zmags.com/publication/6f2ba9ec?page=17"> Cohorts 1 and 2 included both PD-L1 positive (PD-</a> <a title="EMJ Oncology 5.1 2017 page 18" href="http://viewer.zmags.com/publication/6f2ba9ec?page=18"> The FLOT4 study is the first trial to show</a> <a title="EMJ Oncology 5.1 2017 page 19" href="http://viewer.zmags.com/publication/6f2ba9ec?page=19"> suffer from late side effects of their cancer tre</a> <a title="EMJ Oncology 5.1 2017 page 20" href="http://viewer.zmags.com/publication/6f2ba9ec?page=20"> Further Analysis of Treatments for Prostate Cance</a> <a title="EMJ Oncology 5.1 2017 page 21" href="http://viewer.zmags.com/publication/6f2ba9ec?page=21"> Speaking about the results, STAMPEDE’s ch</a> <a title="EMJ Oncology 5.1 2017 page 22" href="http://viewer.zmags.com/publication/6f2ba9ec?page=22"> or undergoing chemotherapy were included in the s</a> <a title="EMJ Oncology 5.1 2017 page 23" href="http://viewer.zmags.com/publication/6f2ba9ec?page=23"> The goal is for the tool to become standard and e</a> <a title="EMJ Oncology 5.1 2017 page 24" href="http://viewer.zmags.com/publication/6f2ba9ec?page=24"> rates when directly compared to chemoradiation al</a> <a title="EMJ Oncology 5.1 2017 page 25" href="http://viewer.zmags.com/publication/6f2ba9ec?page=25"> The study researchers utilised data from nat</a> <a title="EMJ Oncology 5.1 2017 page 26" href="http://viewer.zmags.com/publication/6f2ba9ec?page=26"> placebo. The primary endpoint was measured in th</a> <a title="EMJ Oncology 5.1 2017 page 27" href="http://viewer.zmags.com/publication/6f2ba9ec?page=27"> We were able to detect a reduction in tumour size</a> <a title="EMJ Oncology 5.1 2017 page 28" href="http://viewer.zmags.com/publication/6f2ba9ec?page=28"> they are the ones patients trust the most.” With </a> <a title="EMJ Oncology 5.1 2017 page 29" href="http://viewer.zmags.com/publication/6f2ba9ec?page=29"> Rare Cancers Treated Using Drug Rediscovery by DN</a> <a title="EMJ Oncology 5.1 2017 page 30" href="http://viewer.zmags.com/publication/6f2ba9ec?page=30"> An individual question...  The only mult</a> <a title="EMJ Oncology 5.1 2017 page 31" href="http://viewer.zmags.com/publication/6f2ba9ec?page=31"> Mohammad Akheel Consultant Head and Neck Oncosur</a> <a title="EMJ Oncology 5.1 2017 page 32" href="http://viewer.zmags.com/publication/6f2ba9ec?page=32"> (COMMONDO) surgery with pectoralis major </a> <a title="EMJ Oncology 5.1 2017 page 33" href="http://viewer.zmags.com/publication/6f2ba9ec?page=33"> Q: We understand that the Danish Centre fo</a> <a title="EMJ Oncology 5.1 2017 page 34" href="http://viewer.zmags.com/publication/6f2ba9ec?page=34"> physicists, two seats of the Executive Committee </a> <a title="EMJ Oncology 5.1 2017 page 35" href="http://viewer.zmags.com/publication/6f2ba9ec?page=35"> I believe it is important for all science profess</a> <a title="EMJ Oncology 5.1 2017 page 36" href="http://viewer.zmags.com/publication/6f2ba9ec?page=36"> c c r t S is t v i Q r A i f b c </a> <a title="EMJ Oncology 5.1 2017 page 37" href="http://viewer.zmags.com/publication/6f2ba9ec?page=37"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Oncology 5.1 2017 page 38" href="http://viewer.zmags.com/publication/6f2ba9ec?page=38"> Abstract Reviews DEXAMETHASONE CONTRIBUTES </a> <a title="EMJ Oncology 5.1 2017 page 39" href="http://viewer.zmags.com/publication/6f2ba9ec?page=39"> ESMO 2017 proliferation and tumour progression. </a> <a title="EMJ Oncology 5.1 2017 page 40" href="http://viewer.zmags.com/publication/6f2ba9ec?page=40"> Abstract Reviews diarrhoea were by far the most </a> <a title="EMJ Oncology 5.1 2017 page 41" href="http://viewer.zmags.com/publication/6f2ba9ec?page=41"> ESMO 2017 3. Department of Otolaryngology</a> <a title="EMJ Oncology 5.1 2017 page 42" href="http://viewer.zmags.com/publication/6f2ba9ec?page=42"> Abstract Reviews discuss behavioural changes in </a> <a title="EMJ Oncology 5.1 2017 page 43" href="http://viewer.zmags.com/publication/6f2ba9ec?page=43"> ESMO 2017 with chemotherapy, as its deve</a> <a title="EMJ Oncology 5.1 2017 page 44" href="http://viewer.zmags.com/publication/6f2ba9ec?page=44"> Abstract Reviews Figure 2: RISK Web Predictor. Cl</a> <a title="EMJ Oncology 5.1 2017 page 45" href="http://viewer.zmags.com/publication/6f2ba9ec?page=45"> ESMO 2017 21(S6):vi85-92. 5. European Society of</a> <a title="EMJ Oncology 5.1 2017 page 46" href="http://viewer.zmags.com/publication/6f2ba9ec?page=46"> Abstract Reviews transcriptional level, the anta</a> <a title="EMJ Oncology 5.1 2017 page 47" href="http://viewer.zmags.com/publication/6f2ba9ec?page=47"> ESMO 2017 a negative impact on colorectal cancer</a> <a title="EMJ Oncology 5.1 2017 page 48" href="http://viewer.zmags.com/publication/6f2ba9ec?page=48"> Abstract Reviews REFERENCES 1. Pursnani A et al.</a> <a title="EMJ Oncology 5.1 2017 page 49" href="http://viewer.zmags.com/publication/6f2ba9ec?page=49"> ESMO 2017 was seen in the CB cell population com</a> <a title="EMJ Oncology 5.1 2017 page 50" href="http://viewer.zmags.com/publication/6f2ba9ec?page=50"> Abstract Reviews Cortisol upregulated the exp</a> <a title="EMJ Oncology 5.1 2017 page 51" href="http://viewer.zmags.com/publication/6f2ba9ec?page=51"> ESMO 2017 Citation: EMJ Oncol. 2017;5[1]:50</a> <a title="EMJ Oncology 5.1 2017 page 52" href="http://viewer.zmags.com/publication/6f2ba9ec?page=52"> Abstract Reviews Phosphorylation by WNK1 was fou</a> <a title="EMJ Oncology 5.1 2017 page 53" href="http://viewer.zmags.com/publication/6f2ba9ec?page=53"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Oncology 5.1 2017 page 54" href="http://viewer.zmags.com/publication/6f2ba9ec?page=54"> EDITOR’S PICK This issue’s Editor’s </a> <a title="EMJ Oncology 5.1 2017 page 55" href="http://viewer.zmags.com/publication/6f2ba9ec?page=55"> INTRODUCTION Cancer is one of the leading </a> <a title="EMJ Oncology 5.1 2017 page 56" href="http://viewer.zmags.com/publication/6f2ba9ec?page=56"> the premises of user-friendly, reduced costs</a> <a title="EMJ Oncology 5.1 2017 page 57" href="http://viewer.zmags.com/publication/6f2ba9ec?page=57"> and have achieved a resolution to sin</a> <a title="EMJ Oncology 5.1 2017 page 58" href="http://viewer.zmags.com/publication/6f2ba9ec?page=58"> Table 1: Challenges in the biosensing of epigenet</a> <a title="EMJ Oncology 5.1 2017 page 59" href="http://viewer.zmags.com/publication/6f2ba9ec?page=59"> Some SPR biosensors have been developed for the a</a> <a title="EMJ Oncology 5.1 2017 page 60" href="http://viewer.zmags.com/publication/6f2ba9ec?page=60"> very sensitive, and multiplex detection of differ</a> <a title="EMJ Oncology 5.1 2017 page 61" href="http://viewer.zmags.com/publication/6f2ba9ec?page=61"> 37. Kurita R, Niwa O. DNA methylation analysis t</a> <a title="EMJ Oncology 5.1 2017 page 62" href="http://viewer.zmags.com/publication/6f2ba9ec?page=62"> THE JANUS-FACED ROLE OF CELL-MEDIATED IMMUNE RESP</a> <a title="EMJ Oncology 5.1 2017 page 63" href="http://viewer.zmags.com/publication/6f2ba9ec?page=63"> components, such as immune cells, cell surface mo</a> <a title="EMJ Oncology 5.1 2017 page 64" href="http://viewer.zmags.com/publication/6f2ba9ec?page=64"> Elimination Normal cells Highly im</a> <a title="EMJ Oncology 5.1 2017 page 65" href="http://viewer.zmags.com/publication/6f2ba9ec?page=65"> ANTI-TUMOUR IMMUNE CELLS IN PANCREATIC CANCER Eff</a> <a title="EMJ Oncology 5.1 2017 page 66" href="http://viewer.zmags.com/publication/6f2ba9ec?page=66"> IFN-γ-producing NKT cells correlates with reduced</a> <a title="EMJ Oncology 5.1 2017 page 67" href="http://viewer.zmags.com/publication/6f2ba9ec?page=67"> poorer patient survival.41 We also demonstra</a> <a title="EMJ Oncology 5.1 2017 page 68" href="http://viewer.zmags.com/publication/6f2ba9ec?page=68"> recognise and eliminate tumoural cells is impaire</a> <a title="EMJ Oncology 5.1 2017 page 69" href="http://viewer.zmags.com/publication/6f2ba9ec?page=69"> 36. Hiraoka N et al. Prevalence of FOXP3+ regulat</a> <a title="EMJ Oncology 5.1 2017 page 70" href="http://viewer.zmags.com/publication/6f2ba9ec?page=70"> POST-SURGICAL STRATEGIES FOR PROSTATE CANCER: </a> <a title="EMJ Oncology 5.1 2017 page 71" href="http://viewer.zmags.com/publication/6f2ba9ec?page=71"> ADJUVANT RADIATION THERAPY, SALVAGE RADIATION THE</a> <a title="EMJ Oncology 5.1 2017 page 72" href="http://viewer.zmags.com/publication/6f2ba9ec?page=72"> THE DECISION-MAKING AFTER RADICAL PROSTATECTOMY: </a> <a title="EMJ Oncology 5.1 2017 page 73" href="http://viewer.zmags.com/publication/6f2ba9ec?page=73"> Currently, standard SRT is considered for a PSA v</a> <a title="EMJ Oncology 5.1 2017 page 74" href="http://viewer.zmags.com/publication/6f2ba9ec?page=74"> Den et al.50 tested GC score in the setti</a> <a title="EMJ Oncology 5.1 2017 page 75" href="http://viewer.zmags.com/publication/6f2ba9ec?page=75"> At the moment, clinical application of PTEN still</a> <a title="EMJ Oncology 5.1 2017 page 76" href="http://viewer.zmags.com/publication/6f2ba9ec?page=76"> 296(19):2329-35. 5. Bolla M et al. Postoperative </a> <a title="EMJ Oncology 5.1 2017 page 77" href="http://viewer.zmags.com/publication/6f2ba9ec?page=77"> cancer classifier predicts biochemical failure </a> <a title="EMJ Oncology 5.1 2017 page 78" href="http://viewer.zmags.com/publication/6f2ba9ec?page=78"> PROGNOSTIC AND PREDICTIVE VALUE OF FDG-PET AS </a> <a title="EMJ Oncology 5.1 2017 page 79" href="http://viewer.zmags.com/publication/6f2ba9ec?page=79"> PRETREATMENT POSITRON EMISSION TOMOGRAPHY AND PRO</a> <a title="EMJ Oncology 5.1 2017 page 80" href="http://viewer.zmags.com/publication/6f2ba9ec?page=80"> post-SUVmax after neoadjuvant CRT was one o</a> <a title="EMJ Oncology 5.1 2017 page 81" href="http://viewer.zmags.com/publication/6f2ba9ec?page=81"> 4%; p=0.009). Moreover, PET responders had a rema</a> <a title="EMJ Oncology 5.1 2017 page 82" href="http://viewer.zmags.com/publication/6f2ba9ec?page=82"> information in guiding following treatment modali</a> <a title="EMJ Oncology 5.1 2017 page 83" href="http://viewer.zmags.com/publication/6f2ba9ec?page=83"> reports published on FDG-PET in OC are limited </a> <a title="EMJ Oncology 5.1 2017 page 84" href="http://viewer.zmags.com/publication/6f2ba9ec?page=84"> cancer: results of a prospective multi- center t</a> <a title="EMJ Oncology 5.1 2017 page 85" href="http://viewer.zmags.com/publication/6f2ba9ec?page=85"> UNDERSTANDING THE MICROENVIRONMENT OF MELANOM</a> <a title="EMJ Oncology 5.1 2017 page 86" href="http://viewer.zmags.com/publication/6f2ba9ec?page=86"> a high rate of patient death due to advan</a> <a title="EMJ Oncology 5.1 2017 page 87" href="http://viewer.zmags.com/publication/6f2ba9ec?page=87"> A 10µm B 10µm C </a> <a title="EMJ Oncology 5.1 2017 page 88" href="http://viewer.zmags.com/publication/6f2ba9ec?page=88"> effects on tumour fate. Hypoxia encoura</a> <a title="EMJ Oncology 5.1 2017 page 89" href="http://viewer.zmags.com/publication/6f2ba9ec?page=89"> hyaluronate, hyaluronic acid, or HA. The synthesi</a> <a title="EMJ Oncology 5.1 2017 page 90" href="http://viewer.zmags.com/publication/6f2ba9ec?page=90"> is a protein-coding gene. Linnskog et </a> <a title="EMJ Oncology 5.1 2017 page 91" href="http://viewer.zmags.com/publication/6f2ba9ec?page=91"> CURRENT STATUS OF TARGETING STRATEGY FOR MELANOMA</a> <a title="EMJ Oncology 5.1 2017 page 92" href="http://viewer.zmags.com/publication/6f2ba9ec?page=92"> 12. Bedogni B, Powell MB. Skin hypoxia a promoti</a> <a title="EMJ Oncology 5.1 2017 page 93" href="http://viewer.zmags.com/publication/6f2ba9ec?page=93"> CHEMOTHERAPY FOR EXTRACRANIAL GERM CELL TUMOURS </a> <a title="EMJ Oncology 5.1 2017 page 94" href="http://viewer.zmags.com/publication/6f2ba9ec?page=94"> the under-representation of adolescents </a> <a title="EMJ Oncology 5.1 2017 page 95" href="http://viewer.zmags.com/publication/6f2ba9ec?page=95"> In addition, current chemotherapy regimens a</a> <a title="EMJ Oncology 5.1 2017 page 96" href="http://viewer.zmags.com/publication/6f2ba9ec?page=96"> and cisplatin) regimen has been given for Stage I</a> <a title="EMJ Oncology 5.1 2017 page 97" href="http://viewer.zmags.com/publication/6f2ba9ec?page=97"> SALVAGE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY G</a> <a title="EMJ Oncology 5.1 2017 page 98" href="http://viewer.zmags.com/publication/6f2ba9ec?page=98"> consisting of the chimeric antibody SGN</a> <a title="EMJ Oncology 5.1 2017 page 99" href="http://viewer.zmags.com/publication/6f2ba9ec?page=99"> Table 3: Stem cell therapy combined with conventi</a> <a title="EMJ Oncology 5.1 2017 page 100" href="http://viewer.zmags.com/publication/6f2ba9ec?page=100"> GCT survivors. Also, the increased risk</a> <a title="EMJ Oncology 5.1 2017 page 101" href="http://viewer.zmags.com/publication/6f2ba9ec?page=101"> 21. Rogers PC et al. Treatment of children and ad</a> <a title="EMJ Oncology 5.1 2017 page 102" href="http://viewer.zmags.com/publication/6f2ba9ec?page=102"> germ cell tumor and AML (M7). Bone Marrow Transpl</a> <a title="EMJ Oncology 5.1 2017 page 103" href="http://viewer.zmags.com/publication/6f2ba9ec?page=103"> MALIGNANT PLEURAL MESOTHELIOMA: SPOTLIGHT ON </a> <a title="EMJ Oncology 5.1 2017 page 104" href="http://viewer.zmags.com/publication/6f2ba9ec?page=104"> DIAGNOSIS The ability to differentiate between M</a> <a title="EMJ Oncology 5.1 2017 page 105" href="http://viewer.zmags.com/publication/6f2ba9ec?page=105"> high sensitivity (91%), specificity (100%), a</a> <a title="EMJ Oncology 5.1 2017 page 106" href="http://viewer.zmags.com/publication/6f2ba9ec?page=106"> The use of thyroid transcription factor 1 </a> <a title="EMJ Oncology 5.1 2017 page 107" href="http://viewer.zmags.com/publication/6f2ba9ec?page=107"> SOMAscan™ Protein analysis with a 13-prot</a> <a title="EMJ Oncology 5.1 2017 page 108" href="http://viewer.zmags.com/publication/6f2ba9ec?page=108"> complications at the expense of higher recurrence</a> <a title="EMJ Oncology 5.1 2017 page 109" href="http://viewer.zmags.com/publication/6f2ba9ec?page=109"> Thoracoscopic pleurodesis can be performed by VAT</a> <a title="EMJ Oncology 5.1 2017 page 110" href="http://viewer.zmags.com/publication/6f2ba9ec?page=110"> 18. Galateau-Salle F et al. The 2015 World Health</a> <a title="EMJ Oncology 5.1 2017 page 111" href="http://viewer.zmags.com/publication/6f2ba9ec?page=111"> the effectiveness of pleurodesis in malig</a> <a title="EMJ Oncology 5.1 2017 page 112" href="http://viewer.zmags.com/publication/6f2ba9ec?page=112"> UPCOMING EVENTS 2018 Progress and Controversies i</a> <a title="EMJ Oncology 5.1 2017 page 113" href="http://viewer.zmags.com/publication/6f2ba9ec?page=113"> ONCOLOGY European Lung Cancer Conference 2018 (EL</a> <a title="EMJ Oncology 5.1 2017 page 114" href="http://viewer.zmags.com/publication/6f2ba9ec?page=114"> Buyer’s Guide • ABBVIE, INC. • ACCELOVANCE </a> <a title="EMJ Oncology 5.1 2017 page 115" href="http://viewer.zmags.com/publication/6f2ba9ec?page=115"> Oncology • IPSEN • JANSSEN PHARMACEUTICA • </a> <a title="EMJ Oncology 5.1 2017 page 116" href="http://viewer.zmags.com/publication/6f2ba9ec?page=116"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NEW</a>